Strong Genomics Volume Growth
Overall growth in Genomics was 33%, with Oncology growing at 27% and Hereditary at 37%. Expectations for Hereditary growth have been revised to low to mid-20s instead of mid- to high teens.
Data Licensing Business Success
The Insights business grew 38% in the quarter, with an additional $150 million in total contract value, marking a strong bookings quarter.
Achievement of Positive Adjusted EBITDA
Tempus generated positive adjusted EBITDA for the first time, even with additional expenses from the Paige acquisition.
Sustained Growth in Oncology
Oncology volumes showed a strong performance, and growth is expected to continue at 25% for the next three years.
Foundation Model Progress
Good progress on the foundation model with AstraZeneca and Pathos, with post-training expected to begin early 2026.